Terumo (OTCMKTS:TRUMY) Reaches New 1-Year Low – Time to Sell?

Terumo Corp. (OTCMKTS:TRUMY)’s share price hit a new 52-week low on Monday . The company traded as low as $13.89 and last traded at $14.49, with a volume of 31219 shares trading hands. The stock had previously closed at $14.56.

Terumo Stock Down 0.3%

The company has a current ratio of 2.51, a quick ratio of 1.46 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $21.49 billion, a P/E ratio of 24.19 and a beta of 0.75. The stock has a 50 day moving average price of $15.33 and a 200 day moving average price of $16.63.

Terumo (OTCMKTS:TRUMY) last released its quarterly earnings results on Wednesday, November 12th. The company reported $0.16 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.16. Terumo had a net margin of 12.35% and a return on equity of 9.39%. The firm had revenue of $1.86 billion during the quarter, compared to analyst estimates of $1.75 billion.

About Terumo

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.